top of page
FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
Contat Us
bottom of page